News Search Results
May 21, 2026, 11:00 ET Synakis Announces Close of Oversubscribed Pre-Seed Round
TORONTO, May 21, 2026 /PRNewswire/ - Synakis Corp., a Toronto-based biotechnology company developing ocular therapies for retinal disease and glaucoma, announced today the close of an oversubscribed CAD $2.6 million pre-seed financing
More news about: Synakis
May 21, 2026, 10:15 ET Cell Isolation Market/Cell Separation Market worth $7.97 billion by 2031 | MarketsandMarkets™
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=103931479The cell isolation market is expanding as pharmaceutical and biotechnology companies, clinical laboratories, and academic research institutes increasingly adopt cell separation technologies to support drug discovery, cell-based
More news about: MarketsandMarkets
May 21, 2026, 09:00 ET THE GALIEN FOUNDATION ANNOUNCES 20TH ANNUAL PRIX GALIEN USA AWARDS CEREMONY
The milestone event marks two decades of the Prix Galien USA event, recognizing the most transformative breakthroughs in pharmaceutical, biotechnology, medical technology, and digital health innovation, while honoring the companies, researchers, and innovators whose work has fundamentally changed
More news about: The Galien Foundation
May 21, 2026, 09:00 ET ImmunityBio (IBRX) Facing Lawsuit After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- HBSS
844-916-0895ImmunityBio, Inc. (IBRX) Securities Class Action: ImmunityBio is a biotechnology company focused on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system
More news about: Hagens Berman Sobol Shapiro LLP
May 21, 2026, 09:00 ET Lost Money on Regencell Bioscience Holdings Limited (RGC)? Join Class Action Suit Seeking Recovery - Contact SueWallSt
$1 million annually on research and development. The Wall Street Journal noted in January 2026 that only 20 of the 261 companies in the Nasdaq Biotechnology Index carried a greater market value. The lawsuit contends that this extraordinary valuation disconnect was fueled by trading activity unrelated
More news about: SueWallSt.com
May 21, 2026, 08:23 ET Scientific Longevity Company Immorta Bio Appoints Former Ernst & Young Health Sciences Partner Howard Brooks to Corporate Board of Directors
its Corporate Board of Directors. Mr. Brooks brings more than three decades of experience advising and governing healthcare, life sciences, and biotechnology organizations across corporate strategy, financial oversight, capital formation, governance, and enterprise transformation. During his tenure at
More news about: Immorta Bio Inc.
May 21, 2026, 08:00 ET Origin Agritech Announces Financial Results for the First Half of Fiscal Year 2026
November 2025, Origin executed a patent license agreement with Shunfeng BioTech, bringing the Cas-SF01 gene-editing nuclease into the Company's biotechnology toolkit. The license materially strengthens Origin's position in next-generation corn trait development by pairing Cas-SF01 as a precision-editing
More news about: Origin Agritech Limited
May 21, 2026, 08:00 ET TYRA BIOSCIENCES AND BCAN ESTABLISH MAY 21 AS UPPER TRACT UROTHELIAL CANCER (UTUC) AWARENESS DAY
CARLSBAD, Calif., May 21, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology,
More news about: Tyra Biosciences
May 21, 2026, 06:45 ET Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
May 21, 2026, 01:13 ET Selvita reports Q1 2026 results and launches strategic options review
Sieczkowski, Co-Founder, significant shareholder and Chief Executive Officer of Selvita said:"We are observing a progressive recovery in the biotechnology sector, particularly in the United States. However, the market remains volatile, as reflected, amongst other factors, in our Q1 results. We are focusing
More news about: Selvita S.A.
May 20, 2026, 17:41 ET University of Utah to launch groundbreaking DARPA-backed critical minerals testbed
SMART will serve as a national hub for cutting-edge biotechnology research, providing organizations with tools to develop, test and scale breakthrough technologies, accelerating solutions that directly strengthen
More news about: The University of Utah
May 20, 2026, 16:20 ET BioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO® (vosoritide) in Children with Hypochondroplasia
Patient Information.About BioMarinBioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based
More news about: BioMarin Pharmaceutical Inc.
May 20, 2026, 16:00 ET NKF Names Dr. Marc Hurlbert Chief Executive Officer
addressing critical public health challenges. He is recognized for building collaborations across patient advocacy, academia, government, and the biotechnology and pharmaceutical sectors to drive innovation and improve health outcomes."I am honored to join NKF as its next CEO building off of a rich
More news about: National Kidney Foundation
May 20, 2026, 14:54 ET Maryland's incubators are intentionally breaking down regional silos to create a coordinated statewide innovation infrastructure
instead of duplicating efforts, we can create a more powerful support system for Maryland entrepreneurs across industries including cybersecurity, biotechnology, sustainability, advanced technology, and health innovation."Through this partnership, the incubators will:Pursue
More news about: Nexus
May 20, 2026, 14:41 ET Hippocratic AI Expands Life Sciences Leadership Team as Pharma and Medtech Demand for Voice AI Agents Accelerates
Officer for Hippocratic AI's Life Sciences business, bringing more than two decades of global compliance and legal leadership across pharmaceutical, biotechnology, and medical device companies. Most recently he served as SVP & Chief Compliance and Ethics Officer at Bicycle Therapeutics, a clinical-stage
More news about: Hippocratic AI
May 20, 2026, 10:34 ET /C O R R E C T I O N -- InMed Pharmaceuticals/
into a definitive merger agreement (the "Agreement") for an all-stock transaction with Mentari Therapeutics, Inc. ("Mentari"), a privately-held biotechnology company developing therapies for migraine prevention, Indigo Merger Sub Corp. a wholly-owned subsidiary of InMed, and Indigo Merger Sub II, LLC,
More news about: InMed Pharmaceuticals
May 20, 2026, 10:15 ET High Throughput Screening Market worth $45.90 billion by 2031 | MarketsandMarkets™
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=134981950The high-throughput screening (HTS) market is expected to grow steadily due to increasing drug discovery activity, rising pharmaceutical and biotechnology R&D spending, and the growing need to screen large compound, gene, and cell libraries more efficiently. HTS platforms are now widely used in
More news about: MarketsandMarkets
May 20, 2026, 09:50 ET Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets
(OTCQB: AVAI) ("Avaí" or the "Company"), an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging, today announced—together with its joint venture partner and global biotechnology firm, Austrianova— a major milestone in the Company's
More news about: Market News Updates
May 20, 2026, 09:25 ET Natural Food Additives Market to Reach US$75.2 Billion by 2033 as Clean-Label Innovation Gains Momentum Across Food Industry | Persistence Market Research
StrategiesLeading players include Givaudan, IFF, Kerry Group, ADM, Symrise, DSM-Firmenich, and Indena.Givaudan continues investing in biotechnology and precision fermentation platforms to strengthen natural flavor portfolios and improve ingredient consistency.IFF focuses on clean-label
More news about: Persistence Market Research Pvt. Ltd.
May 20, 2026, 09:21 ET Remepy Reports Strong Clinical Phase IIa Results for Hybridopa™, a First-in-Class Hybrid Drug for Parkinson's Disease
symptoms such as sleep disturbances, depression, and cognitive changes.[2]About RemepyRemepy is a clinical-stage biotechnology company pioneering Hybrid Drugs™ - a therapeutic category that integrates pharmaceutical treatments with personalized digital protocols to improve
More news about: Remepy
May 20, 2026, 09:00 ET RGC Deadline Alert: Levi & Korsinsky Reminds Regencell Bioscience Holdings (RGC) Investors of Securities Class Action Deadline on June 23, 2026
Yet the Company's market value reached approximately $14 billion. As The Wall Street Journal observed, only 20 of the 261 companies in the Nasdaq Biotechnology Index carried a greater market capitalization. The lawsuit contends that this extraordinary valuation had no connection to Regencell's underlying
More news about: Levi & Korsinsky, LLP
May 20, 2026, 08:45 ET Avaí Bio and Austrianova Complete GMP Master Cell Bank, Begin Viral Testing for Cell-Based Klotho Anti-Aging Therapy
(OTCQB: AVAI) ("Avaí" or the "Company"), an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging, today announced—together with its joint venture partner and global biotechnology firm, Austrianova— a major milestone in the Company's
More news about: Avai Bio, Inc.
May 20, 2026, 08:00 ET Pinnaql Acquires Pharma Resource Group, Expanding Engineering, Validation, Tech Transfer, and Manufacturing Support for Life Sciences Clients
acquisition of Pharma Resource Group, Inc. ("PRG"), a specialized consulting firm with nearly two decades of experience supporting pharmaceutical and biotechnology clients across the United States and internationally. The acquisition meaningfully expands Pinnaql's depth across its core service areas and brings
More news about: Pinnaql
May 20, 2026, 08:00 ET Continuity Biosciences Announces First-in-Human Clinical Trial of Precision Drug Delivery Platform for Pancreatic Cancer
N.C. and BRADENTON, Fla., May 20, 2026 /PRNewswire/ -- Continuity Biosciences, LLC, a clinical-stage biotechnology company advancing precision drug delivery platforms, today announced the initiation of a Phase I, first-in-human clinical trial evaluating gemcitabine
More news about: Continuity Biosciences LLC
May 20, 2026, 08:00 ET Continuity Biosciences Announces First-in-Human Clinical Trial of Precision Drug Delivery Platform for Pancreatic Cancer
N.C. and BRADENTON, Fla., May 20, 2026 /PRNewswire/ -- Continuity Biosciences, LLC, a clinical-stage biotechnology company advancing precision drug delivery platforms, today announced the initiation of a Phase I, first-in-human clinical trial evaluating gemcitabine
More news about: Continuity Biosciences LLC